TITLE:
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

CONDITION:
Hepatitis C, Chronic

INTERVENTION:
peginterferon alfa-2a [Pegasys]

SUMMARY:

      This 2-arm study was designed to evaluate the efficacy, safety, and tolerability of
      prophylactic PEGASYS plus COPEGUS after liver transplantation for hepatitis C, compared to
      initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection.
      The anticipated time on study treatment was 3-12 months, and the target sample size was
      100-500 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Adult patients at least 18 years of age

          -  Positive hepatitis C virus RNA at pre-transplantation

          -  Primary, single-organ recipient (cadaveric donor)

          -  Liver transplant between 10 and 16 weeks before treatment initiation

        Exclusion Criteria:

          -  Multi-organ or re-transplant recipient

          -  Evidence of current hepatitis B infection

          -  Seropositive for human immunodeficiency (HIV) infection
      
